Y
Yuh Sakata
Researcher at Hirosaki University
Publications - 131
Citations - 6025
Yuh Sakata is an academic researcher from Hirosaki University. The author has contributed to research in topics: Irinotecan & Cancer. The author has an hindex of 25, co-authored 124 publications receiving 5439 citations.
Papers
More filters
Journal ArticleDOI
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer
Toshiaki Watanabe,Michio Itabashi,Yasuhiro Shimada,Shinji Tanaka,Yoshinori Ito,Yoichi Ajioka,Tetsuya Hamaguchi,Ichinosuke Hyodo,Masahiro Igarashi,Hideyuki Ishida,Megumi Ishiguro,Yukihide Kanemitsu,Norihiro Kokudo,Kei Muro,Atsushi Ochiai,Masahiko Oguchi,Yasuo Ohkura,Yutaka Saito,Yoshiharu Sakai,Hideki Ueno,Takayuki Yoshino,Takahiro Fujimori,Nobuo Koinuma,Takayuki Morita,Genichi Nishimura,Yuh Sakata,Keiichi Takahashi,Hiroya Takiuchi,Osamu Tsuruta,Toshiharu Yamaguchi,Masahiro Yoshida,Naohiko Yamaguchi,Kenjiro Kotake,Kenichi Sugihara,Rectum +34 more
TL;DR: The English version of the JSCCR Guidelines 2016 is presented, which can be used as a tool for treating colorectal cancer in actual clinical practice settings and as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient.
Journal ArticleDOI
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer
Toshiaki Watanabe,Michio Itabashi,Yasuhiro Shimada,Shinji Tanaka,Yoshinori Ito,Yoichi Ajioka,Tetsuya Hamaguchi,Ichinosuke Hyodo,Masahiro Igarashi,Hideyuki Ishida,Soichiro Ishihara,Megumi Ishiguro,Yukihide Kanemitsu,Norihiro Kokudo,Kei Muro,Atsushi Ochiai,Masahiko Oguchi,Yasuo Ohkura,Yutaka Saito,Yoshiharu Sakai,Hideki Ueno,Takayuki Yoshino,Narikazu Boku,Takahiro Fujimori,Nobuo Koinuma,Takayuki Morita,Genichi Nishimura,Yuh Sakata,Keiichi Takahashi,Osamu Tsuruta,Toshiharu Yamaguchi,Masahiro Yoshida,Naohiko Yamaguchi,Kenjiro Kotake,Kenichi Sugihara +34 more
TL;DR: The English version of the JSCCR Guidelines 2014 can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient, and can, therefore, be used for treating colorectal cancer in clinical practice.
Journal ArticleDOI
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur–0.4 M gimestat–1 M otastat potassium) in advanced gastric cancer patients
TL;DR: S-1 improves the tumour-selective toxicity of 5-FU by the actions of two modulators, CDHP and Oxo, and was effective and well tolerated in patients with advanced gastric cancer.
Journal ArticleDOI
Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.
Yasuhiro Shimada,Masahiro Yoshino,Akira Wakui,Isao Nakao,Koichi Futatsuki,Yuh Sakata,Mariko Kambe,Tetsuo Taguchi,Nobuya Ogawa +8 more
TL;DR: CPT-11 showed promising antitumor activity against metastatic colorectal cancer that was resistant to prior therapy and could be continued on an outpatient basis for patients without severe toxicity.
Journal ArticleDOI
Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric Cancer
Narikazu Boku,Atsushi Ohtsu,Yasuhiro Shimada,Kuniaki Shirao,Shigeki Seki,Hiroshi Saito,Yuh Sakata,Ichinosuke Hyodo +7 more
TL;DR: This combination chemotherapy regimen is active and well tolerated and may be an appropriate regimen for future phase III trials.